Forkhead box protein K2 mRNA (FOXK2 mRNA)

Forkhead box protein K2 (FOXK2) mRNA is the transcript encoding the FOXK2 transcription factor, a member of the forkhead box family that regulates essential cellular processes including aerobic glycolysis, autophagy, and the cell cycle [1, 2, 9]. As a therapeutic target, FOXK2 mRNA is primarily investigated in the context of oncology, where it exhibits a complex, context-dependent role as either an oncogene or a tumor suppressor [4, 6]. In cancers such as colorectal and hepatocellular carcinoma, FOXK2 is often overexpressed and promotes tumor progression, making its mRNA a candidate for knockdown via RNA interference (RNAi) or antisense oligonucleotides (ASOs) [2, 6]. Conversely, in breast and lung cancers, FOXK2 can function as a tumor suppressor, suggesting that therapeutic modulation must be highly specific to the disease context [1, 4]. Beyond cancer, FOXK2 is a key regulator of metabolic reprogramming, particularly the Warburg effect, by controlling the expression of glycolytic enzymes and mitochondrial function [9, 10]. While no drugs targeting FOXK2 mRNA are currently FDA-approved, preclinical studies have demonstrated that silencing this mRNA can reduce cell proliferation and sensitize tumors to chemotherapy [5, 10]. The primary challenges in targeting FOXK2 mRNA include achieving effective delivery to target tissues and avoiding off-target effects that could disrupt normal metabolic homeostasis or inadvertently promote tumor growth in certain contexts [2, 16].

Other names

Forkhead box K2 mRNAILF mRNAILF1 mRNAInterleukin enhancer-binding factor 1 mRNAnGTBP mRNA

RNA interference (RNAi) and antisense inhibition to reduce expression of the FOXK2 protein.